The evolution and prognostic impact of HER2-low, HER2-ultralow, and HER2-null status in HER2-negative early breast cancer: A pre- to post-neoadjuvant chemotherapy study.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: residual disease (iDFS, hazard ratio, 0
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] HER2 expression levels (low/ultralow/null) stratify prognosis in HER2-negative eBC. The dynamic evolution of HER2 status following NAC and its prognostic utility highlights the importance of reassessing HER2 status in residual disease in HER2-negative eBC.
[BACKGROUND] The prognostic relevance of HER2-low, HER2-ultralow, and null status in HER2-negative early breast cancer (eBC), and its evolution during neoadjuvant chemotherapy (NAC), remains unclear.
- p-value p < .05
- 95% CI 0.62-0.83
- 추적기간 70.8 months
APA
Qiu Y, Wu L, et al. (2026). The evolution and prognostic impact of HER2-low, HER2-ultralow, and HER2-null status in HER2-negative early breast cancer: A pre- to post-neoadjuvant chemotherapy study.. Cancer, 132(3), e70269. https://doi.org/10.1002/cncr.70269
MLA
Qiu Y, et al.. "The evolution and prognostic impact of HER2-low, HER2-ultralow, and HER2-null status in HER2-negative early breast cancer: A pre- to post-neoadjuvant chemotherapy study.." Cancer, vol. 132, no. 3, 2026, pp. e70269.
PMID
41562542 ↗
Abstract 한글 요약
[BACKGROUND] The prognostic relevance of HER2-low, HER2-ultralow, and null status in HER2-negative early breast cancer (eBC), and its evolution during neoadjuvant chemotherapy (NAC), remains unclear.
[METHODS] The authors analyzed 810 HER2-negative eBC patients (2011-2021) with centrally confirmed pre- and post-NAC HER2 status. Pathologic complete response (pCR, ypT0/is ypN0) rates were analyzed using logistic regression, and invasive disease-free survival (iDFS) and overall survival (OS) were evaluated via multivariable Cox proportional hazards models.
[RESULTS] HER2-null tumors demonstrated significantly higher rates of hormone receptor negativity, grade III histology, and Ki-67 ≥20% compared to HER2-low subgroup (p < .05 for all). The pCR rates were 8.4% (HER2-low), 20.4% (HER2-ultralow), and 25.0% (HER2-null), respectively. HER2 expression inversely correlated with pCR rates across the entire cohort (odds ratio, 0.75; 95% confidence interval [CI], 0.58-0.98; p for trend = .033). After a median follow-up of 70.8 months, survival analysis indicated that higher HER2 expression was associated with significantly improved iDFS (hazard ratio, 0.72; 95% CI, 0.62-0.83) and OS (hazard ratio, 0.67; 95% CI, 0.57-0.80) in the overall population (p for trend <.001 for both). Following NAC, nearly 41.0% of baseline HER2-null tumors converted to HER2-low or ultralow status. Notably, post-NAC HER2 status remained predictive of improved survival in patients with residual disease (iDFS, hazard ratio, 0.72; 95% CI, 0.62-0.84; OS, hazard ratio, 0.65; 95% CI, 0.55-0.78; p for trend <.001 for both).
[CONCLUSION] HER2 expression levels (low/ultralow/null) stratify prognosis in HER2-negative eBC. The dynamic evolution of HER2 status following NAC and its prognostic utility highlights the importance of reassessing HER2 status in residual disease in HER2-negative eBC.
[METHODS] The authors analyzed 810 HER2-negative eBC patients (2011-2021) with centrally confirmed pre- and post-NAC HER2 status. Pathologic complete response (pCR, ypT0/is ypN0) rates were analyzed using logistic regression, and invasive disease-free survival (iDFS) and overall survival (OS) were evaluated via multivariable Cox proportional hazards models.
[RESULTS] HER2-null tumors demonstrated significantly higher rates of hormone receptor negativity, grade III histology, and Ki-67 ≥20% compared to HER2-low subgroup (p < .05 for all). The pCR rates were 8.4% (HER2-low), 20.4% (HER2-ultralow), and 25.0% (HER2-null), respectively. HER2 expression inversely correlated with pCR rates across the entire cohort (odds ratio, 0.75; 95% confidence interval [CI], 0.58-0.98; p for trend = .033). After a median follow-up of 70.8 months, survival analysis indicated that higher HER2 expression was associated with significantly improved iDFS (hazard ratio, 0.72; 95% CI, 0.62-0.83) and OS (hazard ratio, 0.67; 95% CI, 0.57-0.80) in the overall population (p for trend <.001 for both). Following NAC, nearly 41.0% of baseline HER2-null tumors converted to HER2-low or ultralow status. Notably, post-NAC HER2 status remained predictive of improved survival in patients with residual disease (iDFS, hazard ratio, 0.72; 95% CI, 0.62-0.84; OS, hazard ratio, 0.65; 95% CI, 0.55-0.78; p for trend <.001 for both).
[CONCLUSION] HER2 expression levels (low/ultralow/null) stratify prognosis in HER2-negative eBC. The dynamic evolution of HER2 status following NAC and its prognostic utility highlights the importance of reassessing HER2 status in residual disease in HER2-negative eBC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Female
- Breast Neoplasms
- Erb-b2 Receptor Tyrosine Kinases
- Middle Aged
- Prognosis
- Neoadjuvant Therapy
- Adult
- Aged
- Chemotherapy
- Adjuvant
- Biomarkers
- Tumor
- Disease-Free Survival
- Antineoplastic Combined Chemotherapy Protocols
- Retrospective Studies
- HER2‐low breast cancer
- biomarker dynamics
- neoadjuvant chemotherapy
- pathological complete response
- survival outcomes
같은 제1저자의 인용 많은 논문 (5)
- A rare case of variant acute promyelocytic leukemia with fusion gene: case report and literature review.
- Metformin alleviates ribociclib-induced lung injury by restoring impaired autophagy via targeting Mucolipin-1.
- Metal Element-Doped Prussian Blue Enhanced Chemodynamic Therapy and Imaging of Breast Cancer.
- Osimertinib activates TFEB to trigger hepatocyte cytoplasmic vacuolation-associated cell death.
- Reversing ABCB1-Mediated Multidrug Resistance in Colorectal Cancer: electroacupuncture shows therapeutic potential .
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.